Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00444028 · ClinicalTrials.gov registry record · Phase 1
Staccato Loxapine Single Dose PK
A Phase 1 study, sponsored by Alexza Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
NCT00444028 is a Phase 1 study that has completed, run by Alexza Pharmaceuticals. The registered enrollment target is 50 participants.
The verdict
NCT00444028, a Phase 1 study, has completed, sponsored by Alexza Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
Study Summary
The objective of this study was to assess the safety, tolerability and pharmacokinetics of a single inhaled dose of (administered in 1 or 2 puffs) Staccato Loxapine in healthy volunteers.
Interventions
- DRUG inhaled Loxapine 0.625 mg
- DRUG inhaled Loxapine 1.25 mg
- DRUG inhaled Loxapine 2.5 mg
- DRUG inhaled Loxapine 5 mg
- DRUG inhaled Loxapine 10 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2005-09 |
| Est. Completion | 2005-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00444028
The ClinicalTrials.gov registry entry for NCT00444028 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alexza Pharmaceuticals, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which inhaled Loxapine 0.625 mg is the first listed.
NCT00444028 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00444028 about?
NCT00444028 is a clinical study titled "Staccato Loxapine Single Dose PK". The objective of this study was to assess the safety, tolerability and pharmacokinetics of a single inhaled dose of (administered in 1 or 2 puffs) Staccato Loxapine in healthy volunteers.
What is the current status of trial NCT00444028?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2005-09. Estimated completion is 2005-11.
What interventions are being tested in trial NCT00444028?
The interventions under investigation include: inhaled Loxapine 0.625 mg (DRUG), inhaled Loxapine 1.25 mg (DRUG), inhaled Loxapine 2.5 mg (DRUG), inhaled Loxapine 5 mg (DRUG), inhaled Loxapine 10 mg (DRUG).
Who is sponsoring clinical trial NCT00444028?
This trial is sponsored by Alexza Pharmaceuticals, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.